Immunomedics, Inc. (NASDAQ:IMMU) Director David M. Goldenberg sold 40,000 shares of the company’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $17.24, for a total transaction of $689,600.00. Following the completion of the transaction, the director now directly owns 1,774,285 shares of the company’s stock, valued at $30,588,673.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Immunomedics, Inc. (IMMU) opened at $16.94 on Wednesday. The firm has a market cap of $2,580.00, a price-to-earnings ratio of -9.11 and a beta of 1.48. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.26 and a quick ratio of 1.26. Immunomedics, Inc. has a one year low of $5.00 and a one year high of $18.93.

How to Become a New Pot Stock Millionaire

Immunomedics (NASDAQ:IMMU) last issued its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.09). The business had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $0.90 million. analysts predict that Immunomedics, Inc. will post -0.96 earnings per share for the current year.

A number of large investors have recently modified their holdings of IMMU. The Manufacturers Life Insurance Company lifted its position in Immunomedics by 2.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 79,520 shares of the biopharmaceutical company’s stock worth $702,000 after buying an additional 1,763 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its position in Immunomedics by 11.4% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 1,473 shares in the last quarter. Swiss National Bank lifted its position in Immunomedics by 4.3% during the 3rd quarter. Swiss National Bank now owns 156,650 shares of the biopharmaceutical company’s stock worth $2,190,000 after buying an additional 6,400 shares in the last quarter. Jennison Associates LLC lifted its position in Immunomedics by 67.0% during the 3rd quarter. Jennison Associates LLC now owns 1,811,719 shares of the biopharmaceutical company’s stock worth $25,328,000 after buying an additional 726,723 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its position in Immunomedics by 25.3% during the 3rd quarter. New York State Common Retirement Fund now owns 130,325 shares of the biopharmaceutical company’s stock worth $1,822,000 after buying an additional 26,325 shares in the last quarter. 74.52% of the stock is currently owned by hedge funds and other institutional investors.

IMMU has been the subject of a number of research analyst reports. Jefferies Group upped their target price on shares of Immunomedics from $22.00 to $27.00 and gave the stock a “buy” rating in a research note on Wednesday, January 24th. BidaskClub raised shares of Immunomedics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 25th. ValuEngine raised shares of Immunomedics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research lowered shares of Immunomedics from a “hold” rating to a “sell” rating in a research note on Saturday, February 17th. Finally, TheStreet raised shares of Immunomedics from a “d” rating to a “c-” rating in a research note on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $19.00.

TRADEMARK VIOLATION WARNING: “David M. Goldenberg Sells 40,000 Shares of Immunomedics, Inc. (IMMU) Stock” was reported by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2018/03/14/david-m-goldenberg-sells-40000-shares-of-immunomedics-inc-immu-stock.html.

About Immunomedics

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Insider Buying and Selling by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.